Last reviewed · How we verify

Imipramine, pregabalin

Odense University Hospital · FDA-approved active Small molecule

This combination of a tricyclic antidepressant and a gabapentinoid works by increasing norepinephrine and serotonin availability while modulating calcium channels to reduce neuronal excitability.

This combination of a tricyclic antidepressant and a gabapentinoid works by increasing norepinephrine and serotonin availability while modulating calcium channels to reduce neuronal excitability. Used for Neuropathic pain with comorbid depression, Anxiety disorders with neuropathic pain.

At a glance

Generic nameImipramine, pregabalin
Also known asImipramin DAK, Lyrica
SponsorOdense University Hospital
Drug classTricyclic antidepressant + gabapentinoid combination
TargetNorepinephrine transporter, serotonin transporter, alpha-2-delta calcium channel subunit
ModalitySmall molecule
Therapeutic areaPsychiatry, Neurology, Pain Management
PhaseFDA-approved

Mechanism of action

Imipramine blocks the reuptake of norepinephrine and serotonin at nerve terminals, increasing their synaptic concentrations. Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels, reducing calcium influx and subsequent neurotransmitter release. Together, these mechanisms address both mood and neuropathic pain pathways.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results